Oxford Biomedica plc (OXOA)
Market Closed
16 Jul, 17:33
€
7. 50
0
0%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 7.5
Previous Close Want to track OXOA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
OXOA closed Thursday higher at €7.5, an increase of 0% from Wednesday's close, completing a monthly increase of 7.9137% or €0.55. Over the past 12 months, OXOA stock gained 10.2941%.
OXOA is not paying dividends to its shareholders.
The last earnings report, released on Apr 07, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0361%, based on the last three reports.
Oxford Biomedica plc has completed 6 stock splits, with the recent split occurring on May 30, 2018.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on LSE (GBX).
OXOA Chart
Oxford Biomedica plc (OXOA) FAQ
What is the stock price today?
The current price is €7.50.
On which exchange is it traded?
Oxford Biomedica plc is listed on XDUS.
What is its stock symbol?
The ticker symbol is OXOA.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Oxford Biomedica plc ever had a stock split?
Oxford Biomedica plc had 6 splits and the recent split was on May 30, 2018.
Oxford Biomedica plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Frank Mathias CEO | XDUS Exchange | GB00BDFBVT43 ISIN |
| GB Country | 977 Employees | - Last Dividend | 30 May 2018 Last Split | - IPO Date |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Contact Information
Address: Windrush Court, Oxford, United Kingdom, OX4 6LT
Phone: 44 1865 783 000
Website: https://www.oxb.com
